Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-191-5118500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£14.00 million
Profitability
Miscellaneous
Employees15
Next Earnings DateN/A
OptionableOptionable
Shield Therapeutics (LON:STX) Frequently Asked Questions
What is Shield Therapeutics' stock symbol?
Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."
What price target have analysts set for STX?
2 analysts have issued 12 month target prices for Shield Therapeutics' stock. Their forecasts range from GBX 116 to GBX 200. On average, they anticipate Shield Therapeutics' stock price to reach GBX 172 in the next year. This suggests that the stock has a possible downside of 5.0%. View Analyst Price Targets for Shield Therapeutics.
What is the consensus analysts' recommendation for Shield Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.
Has Shield Therapeutics been receiving favorable news coverage?
Media coverage about STX stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Shield Therapeutics earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Shield Therapeutics.
Who are some of Shield Therapeutics' key competitors?
Some companies that are related to Shield Therapeutics include Green Organic Dutchman (TGOD), OrganiGram (OGI), Supreme Cannabis (FIRE), HLS Therapeutics (HLS), Flowr (FLWR), CannTrust (TRST), Benchmark (BMK), ICC Labs (ICC), Althea Group (AGH), WeedMD (WMD), Auscann Group (AC8), Probiotec (PBP), Harvest One Cannabis (HVT), Delta 9 Cannabis (NINE) and Depomed (ASRT).
What other stocks do shareholders of Shield Therapeutics own?
Who are Shield Therapeutics' key executives?
Shield Therapeutics' management team includes the folowing people:
- Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
- Mr. Timothy William Watts, Chief Financial Officer (Age 61)
- Fleur Wood, Director of Investor Relations
- Ms. Lucy Bailey, Gen. Counsel & Company Sec.
- Ms. Suzanne Wood, Group HR Director
How do I buy shares of Shield Therapeutics?
Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Shield Therapeutics' stock price today?
One share of STX stock can currently be purchased for approximately GBX 181.
How big of a company is Shield Therapeutics?
What is Shield Therapeutics' official website?
How can I contact Shield Therapeutics?
Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.
MarketBeat Community Rating for Shield Therapeutics (LON STX)
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
